These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31353229)

  • 1. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
    Jin C; Hacking S; Liang S; Nasim M
    Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Immunohistochemical Expression in Undifferentiated/Dedifferentiated Endometrial Carcinoma.
    Cao J; Hacking S; Chavarria-Bernal HD; Bhuiya TA; Khutti S
    Int J Gynecol Pathol; 2022 Jan; 41(1):28-34. PubMed ID: 33399351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
    Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J
    Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.
    Gan Q; Crumley S; Broaddus RR
    Int J Gynecol Pathol; 2019 Jan; 38(1):44-51. PubMed ID: 29210800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression.
    Stewart CJR; Pearn A; Pachter N; Tan A
    Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
    Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
    Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.